Special Issue "Melanoma Metastasis: New and Evolving Concepts"
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 7726
Deepening understanding of melanoma biology and host immunology has translated into major advances in managing melanoma in recent years. Molecularly targeted agents in the form of BRAF-MEK inhibitor combinations for BRAF mutant melanoma and immune checkpoint inhibitors targeting CTLA4, PD1, and LAG3 have drastically transformed clinical care. Despite these improvements, primary and acquired resistance remain a major barrier to successful treatment and, ultimately, long-term survival. Therefore, defining the underlying resistance mechanisms will be vital to improve the outcomes of the majority of patients, and understanding the biology behind clinical responses will be key to personalized treatment. In addition, determining the optimal treatment sequence for each patient may maximize the likelihood of clinical benefits. Enhancing our understanding of emerging technological advances combined with a growing knowledge of tumor biology and host immunology present major opportunities to better guide drug development in this disease.
This Special Issue will address evolving research topics related to neoadjuvant therapy of locoregionally advanced melanoma and first- and second-line treatment of metastatic melanoma. We will also address promising therapeutic agents under investigation in the anti-PD1 failure setting including adoptive cellular therapy and emerging mechanisms of immune resistance. Finally, we will review promising biomarkers of prognostic and therapeutic predictive value that may have applications in the clinic.
Prof. Ahmad Tarhini
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune resistance
- adoptive cellular therapy
- uveal melanoma